Skip to content

Damora Therapeutics, Inc.

DMRA· NasdaqCore metricsCIK 1800315

Pharmaceutical preparations552 peers

Last sale
Nov 12, 2026 · -5.12%
Market cap
$1.36B
61.9M shares
Filings
353
—
—
—
-$31.99M
Q3 2026N/M FY25 yoy
-$36.86M
Q3 2026N/M FY25 yoy
-$43.13M
FY 2022derivedN/M FY22 yoy
-$0.40
Q3 2026N/M FY25 yoy
$349.66M
Q3 2026+1,717.5% FY25 yoy
$1.36B
—
—
2.8×
—
—

FY2025 figures · derived

Price

$22.046.53%$1.54past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Net Interest Income

$1.17MFY 2025
$1.69M0FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$1,167,000reported
FY 20242024-12-31$844,000reported
FY 20232023-12-31$1,689,000reported
FY 20222022-12-31$722,000reported
FY 20212021-12-31$156,000reported

Pharmaceutical preparations

Damora Therapeutics, Inc. is the 126th largest of the 553 covered companies the SEC files under this code, by market cap. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Damora Therapeutics, Inc. · CIK 1800315 · Engraved from SEC EDGAR